MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).

Jeffrey Matous; David Samuel DiCapua Siegel; Hien Kim Duong; Claudia Kasserra; Lars Sternas; Christian Jacques; Kenneth Klesczewski; Mohamed H. Zaki; Jatin J. Shah

doi:10.1200/JCO.2013.31.15_SUPPL.8585

MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).

Jeffrey Matous
, David Samuel DiCapua Siegel
, Hien Kim Duong
, Claudia Kasserra
, Lars Sternas
, Christian Jacques
, Kenneth Klesczewski
, Mohamed H. Zaki
, Jatin J. Shah

Colorado Blood Cancer Institute, Denver, CO
Hackensack University Medical Center
Cleveland Clinic
Celgene
University of Texas MD Anderson Cancer Center

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	31
DOIs	https://doi.org/10.1200/JCO.2013.31.15_SUPPL.8585
State	Published - May 20 2013
Externally published	Yes

Disciplines

Pharmacology
Medicine and Health Sciences
Urology

Access to Document

10.1200/JCO.2013.31.15_SUPPL.8585License: Unspecified

Cite this

Matous, J., Siegel, D. S. D., Duong, H. K., Kasserra, C., Sternas, L., Jacques, C., Klesczewski, K., Zaki, M. H., & Shah, J. J. (2013). MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI). Journal of Clinical Oncology, 31. https://doi.org/10.1200/JCO.2013.31.15_SUPPL.8585

MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI). / Matous, Jeffrey; Siegel, David Samuel DiCapua; Duong, Hien Kim et al.
In: Journal of Clinical Oncology, Vol. 31, 20.05.2013.

Research output: Contribution to journal › Article › peer-review

Matous, J, Siegel, DSD, Duong, HK, Kasserra, C, Sternas, L, Jacques, C, Klesczewski, K, Zaki, MH & Shah, JJ 2013, 'MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).', Journal of Clinical Oncology, vol. 31. https://doi.org/10.1200/JCO.2013.31.15_SUPPL.8585

@article{6e1ab26af4eb421c852bf33b7597cf56,

title = "MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).",

author = "Jeffrey Matous and Siegel, \{David Samuel DiCapua\} and Duong, \{Hien Kim\} and Claudia Kasserra and Lars Sternas and Christian Jacques and Kenneth Klesczewski and Zaki, \{Mohamed H.\} and Shah, \{Jatin J.\}",

note = "8585\textasciicircum{} Background: POM + LoDEX has shown significant clinical activity in RRMM pts including those refractory to lenalidomide and bortezomib. Renal impairment is a common comorbidity for MM pts, occurring in > 40\%. POM is extensively metabolized with less than 5\% renally eliminated as parent drug.",

year = "2013",

month = may,

day = "20",

doi = "10.1200/JCO.2013.31.15\_SUPPL.8585",

language = "American English",

volume = "31",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).

AU - Matous, Jeffrey

AU - Siegel, David Samuel DiCapua

AU - Duong, Hien Kim

AU - Kasserra, Claudia

AU - Sternas, Lars

AU - Jacques, Christian

AU - Klesczewski, Kenneth

AU - Zaki, Mohamed H.

AU - Shah, Jatin J.

N1 - 8585^ Background: POM + LoDEX has shown significant clinical activity in RRMM pts including those refractory to lenalidomide and bortezomib. Renal impairment is a common comorbidity for MM pts, occurring in > 40%. POM is extensively metabolized with less than 5% renally eliminated as parent drug.

PY - 2013/5/20

Y1 - 2013/5/20

UR - https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.8585

U2 - 10.1200/JCO.2013.31.15_SUPPL.8585

DO - 10.1200/JCO.2013.31.15_SUPPL.8585

M3 - Article

VL - 31

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).

Disciplines

Access to Document

Other files and links

Cite this